141 related articles for article (PubMed ID: 26848023)
1. Piperlongumine exerts cytotoxic effects against cancer cells with mutant p53 proteins at least in part by restoring the biological functions of the tumor suppressor.
Basak D; Punganuru SR; Srivenugopal KS
Int J Oncol; 2016 Apr; 48(4):1426-36. PubMed ID: 26848023
[TBL] [Abstract][Full Text] [Related]
2. Design and synthesis of a C7-aryl piperlongumine derivative with potent antimicrotubule and mutant p53-reactivating properties.
Punganuru SR; Madala HR; Venugopal SN; Samala R; Mikelis C; Srivenugopal KS
Eur J Med Chem; 2016 Jan; 107():233-44. PubMed ID: 26599530
[TBL] [Abstract][Full Text] [Related]
3. Selective killing of human breast cancer cells by the styryl lactone (R)-goniothalamin is mediated by glutathione conjugation, induction of oxidative stress and marked reactivation of the R175H mutant p53 protein.
Punganuru SR; Madala HR; Arutla V; Srivenugopal KS
Carcinogenesis; 2018 Dec; 39(11):1399-1410. PubMed ID: 30010803
[TBL] [Abstract][Full Text] [Related]
4. Role of the p53/p21 system in the response of human colon carcinoma cells to Doxorubicin.
Ravizza R; Gariboldi MB; Passarelli L; Monti E
BMC Cancer; 2004 Dec; 4():92. PubMed ID: 15601469
[TBL] [Abstract][Full Text] [Related]
5. Photodynamic therapy resistant human colon carcinoma HT29 cells show cross-resistance to UVA but not UVC light.
Zacal N; Rainbow AJ
Photochem Photobiol; 2007; 83(3):730-7. PubMed ID: 17576382
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of glucosylceramide synthase eliminates the oncogenic function of p53 R273H mutant in the epithelial-mesenchymal transition and induced pluripotency of colon cancer cells.
Hosain SB; Khiste SK; Uddin MB; Vorubindi V; Ingram C; Zhang S; Hill RA; Gu X; Liu YY
Oncotarget; 2016 Sep; 7(37):60575-60592. PubMed ID: 27517620
[TBL] [Abstract][Full Text] [Related]
7. P53-mediated upregulation of DcR1 impairs oxaliplatin/TRAIL-induced synergistic anti-tumour potential in colon cancer cells.
Toscano F; Fajoui ZE; Gay F; Lalaoui N; Parmentier B; Chayvialle JA; Scoazec JY; Micheau O; Abello J; Saurin JC
Oncogene; 2008 Jul; 27(30):4161-71. PubMed ID: 18345033
[TBL] [Abstract][Full Text] [Related]
8. Piperlongumine inhibits the proliferation and survival of B-cell acute lymphoblastic leukemia cell lines irrespective of glucocorticoid resistance.
Han SS; Han S; Kamberos NL
Biochem Biophys Res Commun; 2014 Sep; 452(3):669-75. PubMed ID: 25193702
[TBL] [Abstract][Full Text] [Related]
9. Reactivation of wild-type and mutant p53 by tryptophanolderived oxazoloisoindolinone SLMP53-1, a novel anticancer small-molecule.
Soares J; Raimundo L; Pereira NA; Monteiro Â; Gomes S; Bessa C; Pereira C; Queiroz G; Bisio A; Fernandes J; Gomes C; Reis F; Gonçalves J; Inga A; Santos MM; Saraiva L
Oncotarget; 2016 Jan; 7(4):4326-43. PubMed ID: 26735173
[TBL] [Abstract][Full Text] [Related]
10. In vivo evaluation of the role of DNp73alpha protein in regulating the p53-dependent apoptotic pathway after treatment with cytotoxic drugs.
Sabatino MA; Previdi S; Broggini M
Int J Cancer; 2007 Feb; 120(3):506-13. PubMed ID: 17096333
[TBL] [Abstract][Full Text] [Related]
11. Piperlongumine and p53-reactivator APR-246 selectively induce cell death in HNSCC by targeting GSTP1.
Hang W; Yin ZX; Liu G; Zeng Q; Shen XF; Sun QH; Li DD; Jian YP; Zhang YH; Wang YS; Quan CS; Zhao RX; Li YL; Xu ZX
Oncogene; 2018 Jun; 37(25):3384-3398. PubMed ID: 29348462
[TBL] [Abstract][Full Text] [Related]
12. Small-molecule modulators of p53 family signaling and antitumor effects in p53-deficient human colon tumor xenografts.
Wang W; Kim SH; El-Deiry WS
Proc Natl Acad Sci U S A; 2006 Jul; 103(29):11003-8. PubMed ID: 16835297
[TBL] [Abstract][Full Text] [Related]
13. An N
Uddin MB; Roy KR; Hosain SB; Khiste SK; Hill RA; Jois SD; Zhao Y; Tackett AJ; Liu YY
Biochem Pharmacol; 2019 Feb; 160():134-145. PubMed ID: 30578766
[TBL] [Abstract][Full Text] [Related]
14. TAR1, a human anti-p53 single-chain antibody, restores tumor suppressor function to mutant p53 variants.
Orgad S; Dimant H; Dor-On E; Azriel-Rosenfeld R; Benhar I; Solomon B
J Immunother; 2010; 33(2):146-54. PubMed ID: 20139776
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53.
Van Maerken T; Ferdinande L; Taildeman J; Lambertz I; Yigit N; Vercruysse L; Rihani A; Michaelis M; Cinatl J; Cuvelier CA; Marine JC; De Paepe A; Bracke M; Speleman F; Vandesompele J
J Natl Cancer Inst; 2009 Nov; 101(22):1562-74. PubMed ID: 19903807
[TBL] [Abstract][Full Text] [Related]
16. Acriflavine enhances radiosensitivity of colon cancer cells through endoplasmic reticulum stress-mediated apoptosis.
Lim MJ; Ahn JY; Han Y; Yu CH; Kim MH; Lee SL; Lim DS; Song JY
Int J Biochem Cell Biol; 2012 Aug; 44(8):1214-22. PubMed ID: 22564437
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy-induced O(6)-benzylguanine-resistant alkyltransferase mutations in mismatch-deficient colon cancer.
Liu L; Schwartz S; Davis BM; Gerson SL
Cancer Res; 2002 Jun; 62(11):3070-6. PubMed ID: 12036916
[TBL] [Abstract][Full Text] [Related]
18. Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression.
Bossi G; Lapi E; Strano S; Rinaldo C; Blandino G; Sacchi A
Oncogene; 2006 Jan; 25(2):304-9. PubMed ID: 16170357
[TBL] [Abstract][Full Text] [Related]
19. Antisense anti-MDM2 oligonucleotides as a novel therapeutic approach to human breast cancer: in vitro and in vivo activities and mechanisms.
Wang H; Nan L; Yu D; Agrawal S; Zhang R
Clin Cancer Res; 2001 Nov; 7(11):3613-24. PubMed ID: 11705884
[TBL] [Abstract][Full Text] [Related]
20. Targeted cytotoxic somatostatin analogue AN-238 inhibits somatostatin receptor-positive experimental colon cancers independently of their p53 status.
Szepeshazi K; Schally AV; Halmos G; Armatis P; Hebert F; Sun B; Feil A; Kiaris H; Nagy A
Cancer Res; 2002 Feb; 62(3):781-8. PubMed ID: 11830533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]